Darzalexhcp.com Website Review

DARZALEX® REDEFINING APPROACHES IN EARLY-LINE MULTIPLE MYELOMA TREATMENT. †Prior therapies included a PI and an immunomodulatory agent or patients were double-refractory to a PI and an immunomodulatory agent. Please see Complete Indications and Usage for more information. >52,000 Patients Treated Estimated Worldwide Since Approval2‡ ‡As of June 2018. Estimate based on projected patients, calculations of demand, and duration of treatment. DARZALEX® is a CD38-targeted cytolytic antibody indicated1: and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy two prior therapies including lenalidomide and a proteasome inhibitor (PI) including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent Revlimid® and Pomalyst® are registered trademarks of Celgene Corporation. Velcade® is a registered trademark of Millennium Pharmaceuticals, Inc. DARZALEX® is contraindicated in patients with a history of severe hypersensitivity (eg, anaphylactic reactions) to daratumumab or any of trials, approximately half of all patients experienced an infusion reaction. Most infusion reactions occurred during the first infusion and were grade 1-2. Infusion reactions can also occur with subsequent infusions. Nearly all reactions occurred during infusion or within 4 hours of completing an infusion. Prior to the introduction of post-infusion medication in clinical trials, infusion reactions occurred up to 48 hours after infusion. Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema. Signs and symptoms may include respiratory symptoms, such as nasal congestion, cough, th*oat irritation, as well as chills, vomiting and nausea. Less common symptoms were wheezing, allergic rhinitis, pyrexia, chest discomfort, Pre-medicate patients with antihistamines, antipyretics, and corticosteroids. Frequently monitor patients during the entire